Epirubicin
Childhood Malignant Neoplasm
Children's Hospital Medical Center, CincinnatiUNKNOWNPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
30 Active assets in the Childhood Malignant Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-Vincristine Tianjin Medical University Cancer Institute and Hospital | Phase 2 | BB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | BB |
Nivolumab Australian & New Zealand Children's Haematology/Oncology Group | Phase 2 | B |
Dexasone Yizhuo Zhang | Phase 3 | B |
OTL-38 Mayo Clinic | Phase 3 | B |
View all 50 →
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →